OR WAIT null SECS
© 2023 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 22, 2021.
The US Food and Drug Administration (FDA) approved adalimumab-adbm (Cyltezo), the first interchangeable biosimilar to treat inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis.
Click the image to view the story.
Jeffrey Stark, MD, discusses the recent studies, BE BRIGHT, BE SURE, and BE VIVID, in which investigators analyzed the impact bimekizumab had on patients with psoriasis.
Click the image to view the story.
Dactylitis, a uniform swelling of an entire digit, occurs in up to half of patients with psoriatic arthritis and is sometimes the first manifestation of the condition.
Click the image to view the story.